Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: A phase 2 consortium/stand up 2 cancer study

Authors

Nilofer S. Azad, The Johns Hopkins University
Douglas Adkins, Washington University School of Medicine in St. Louis
Joel Picus, Washington University School of Medicine in St. Louis
Richard Piekarz, Washington University School of Medicine in St. Louis
et al

Journal

Oncotarget

Publication Date

5-23-2017

Volume

8

Issue

21

First Page

35326

Last Page

35338

Document Type

Open Access Publication

DOI

10.18632/oncotarget.15108

Rights and Permissions

Azad NS, El-Khoueiry A, Yin J, Oberg AL, Flynn P, Adkins D, Sharma A, Weisenberger DJ, Brown T, Medvari P, Jones PA, Easwaran H, Kamel I, Bahary N, Kim G, Picus J, Pitot HC, Erlichman C, Donehower R, Shen H, Laird PW, Piekarz R, Baylin S, Ahuja N. Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand up 2 cancer study. Oncotarget. 2017 May 23;8(21):35326-35338. doi: 10.18632/oncotarget.15108. Copyright: Azad et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC-BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Recommended Citation

Azad, Nilofer S.; Adkins, Douglas; Picus, Joel; Piekarz, Richard; and et al, "Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: A phase 2 consortium/stand up 2 cancer study." Oncotarget. 8, 21. 35326 - 35338. (2017).
https://digitalcommons.wustl.edu/open_access_pubs/9026